Navigation Links
OPKO Health Announces Issuance of U.S. Patent Covering the Use and Administration of Certain Anti-VEGF siRNA's, Including Its Phase III Compound Bevasiranib
Date:3/18/2008

-Second Issued Patent for Bevasiranib Broadly Covers siRNA Targeting of VEGF Expression, Further Strengthening OPKO's RNAi Intellectual Property

Portfolio-

MIAMI, March 18 /PRNewswire-FirstCall/ -- OPKO Health, Inc. (Amex: OPK) today announced that it has been issued a key patent by the United States Patent and Trademark Office (USPTO) for methods related to the use and administration of small interfering RNAs (siRNAs) for targeting vascular endothelial growth factor (VEGF), including OPKO's siRNA drug candidate, bevasiranib, which is currently in a Phase III trial for the treatment of wet age-related macular degeneration (AMD).

The claims of the newly issued patent cover a broad range of methods for the use of a specific sequence of siRNA, including bevasiranib, to target VEGF. The patent also covers application of this specific sequence of siRNA to inhibit the expression of VEGF and to treat VEGF-related angiogenic disorders including age-related macular degeneration, diabetic retinopathy and cancer. In addition, the claims cover any methods of administering the siRNA, including intravenous administration, retinal injections and oral administration. This newly issued patent broadly protecting the applications of OPKO's siRNA bevasiranib is the second for the compound. In late 2006, the USPTO issued a patent covering bevasiranib's composition of matter.

"This patent marks another important step in establishing OPKO's leadership position in the promising field of siRNA-based therapeutics," said Samuel Reich, Executive Vice President of OPKO Ophthalmics. "Bevasiranib was the first siRNA to enter human trials, the first siRNA to demonstrate clinically relevant activity in patients, the
'/>"/>

SOURCE OPKO Health, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
3. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
4. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
5. Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry
6. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
7. InterCure and Omron Healthcare (UK) Ltd. Announce Marketing Collaboration for Hypertension Market in United Kingdom
8. Apria Healthcare Chooses Masimo SET Pulse Oximetry for Use in the Companys Home Health Care Business
9. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
10. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
11. Boston Scientific to Participate in the Bear Stearns 20th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... 2014 The “Chiral Chromatography Columns ... Material (Metal, Glass, Plastic), by Application [GC, LC ... Forecast to 2018” analyses and studies the major ... America, Europe, Asia, and Rest of the World. ... figures spread through 135 pages and in-depth TOC ...
(Date:11/21/2014)...   TRU-D SmartUVC LLC and its UK partners, ... disinfection robot, TRU-D SmartUVC, at FIS 2014 in ... 26 at Stand 23. The conference, hosted by ... largest infection-related event of its kind and brings ... the leading events of its type throughout the world. This ...
(Date:11/21/2014)... The report, "Synthetic Biology Market ... kits), Technology (Bioinformatics, Nanotechnology, Gene Synthesis, Cloning ... - Global Forecast to 2018", analyses and ... and challenges. , Browse 99 market data ... pages and in-depth TOC of the global ...
(Date:11/21/2014)... (PRWEB) November 21, 2014 2014 ... a professional and in-depth research report on the ... its definition, classification, application, and industry chain structure ... the international market analysis, including China’s domestic market ... environment & economic situation analysis. The report also ...
Breaking Biology Technology:Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 3Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 4Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 5TRU-D SmartUVC to Showcase Superbug-Killing Robot at FIS 2014 2TRU-D SmartUVC to Showcase Superbug-Killing Robot at FIS 2014 3Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 2Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 3Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 4International Transformer Industry - Analysis on Applications, Development & Forecasts Now Available at ReportsnReports.com 2International Transformer Industry - Analysis on Applications, Development & Forecasts Now Available at ReportsnReports.com 3
... Olympus has further,cemented its position as a leader ... exclusive and immediate deal to distribute the products of,Irish ... global,provider of ports for state-of-the-art laparoscopic operative techniques via,a ... now the exclusive,distributor for the full range of products ...
... 11 Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today ... Directors, unexpectedly passed away on Wednesday. Dr. Waltz had been ... At the time of his death, Dr. Waltz served on ... , "The sudden loss of our ...
... Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY ) announced ... endpoint in its multi-centre Phase 2 clinical trial ... patients with various sarcomas that have metastasized to ... patients on study with significant, durable, clinically meaningful ...
Cached Biology Technology:Minimally Invasive Surgery: Olympus Further Enhances Credentials by Entering Into Exclusive Sales and Distribution Partnership With Market and Technology Leader Advanced Surgical Concepts 2Peregrine Pharmaceuticals Mourns Loss of Chairman Thomas A. Waltz 2Oncolytics Biotech Inc.'s REOLYSIN(R) Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study 2Oncolytics Biotech Inc.'s REOLYSIN(R) Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study 3Oncolytics Biotech Inc.'s REOLYSIN(R) Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study 4
(Date:11/21/2014)... REDMOND, Wash. , Nov. 20, 2014 ... access for the Internet of Things (IoT), today announced ... position of chief operating officer. Previously a strategic advisor ... marketing, finance, and operations. Mr. Traynor is based out ... . He reports to Chris Muench , ...
(Date:11/18/2014)...   News Highlights: ... The Partners Data Lake, an agile data and ... will allow researcher and clinicians to explore and ... lives of patients , The Partners Data ... the Partners system, breaking down physical barriers for ...
(Date:11/15/2014)...  While we may still be a few years away ... Trek" to gain instant access to all that ailed his ... and tablets for monitoring and measuring our health are cropping ... seem a tad Orwellian to some, but a new survey ... technological opportunities into their healthcare regime. These are ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4
... of Velociraptor rewrites evolutionary charts , The recent ... that dromaeosaurs, a group of carnivorous theropods that ... originated much earlier than previously thought. Rather than ... traced back to the Jurassic, possibly as far ...
... a pheromone emitted by older male elephants in musth influences ... surrounding elephants behave, a new study has found. , ... University of Auckland in New Zealand say the release of ... frontalin, depends on whether the male elephant is mature enough ...
... immune system to absorb and digest pathogenic intruders. Some ... multiply within the macrophages. Cell biologists at the University ... recently publication in the journal 'Traffic' (Vol. 6, No. ... pathogens escape the 'stomach' of the macrophages which might ...
Cached Biology News:Newly discovered birdlike dinosaur is oldest raptor ever found in South America 2Newly discovered birdlike dinosaur is oldest raptor ever found in South America 3Newly discovered birdlike dinosaur is oldest raptor ever found in South America 4Male elephants woo females with precise chemistry 2Male elephants woo females with precise chemistry 3Dangerous tricksters: Some bacterie use immune cells to reproduce 2Dangerous tricksters: Some bacterie use immune cells to reproduce 3
Recognizes the VZV nucleocapsid by indirect immunofluorescence and immunoprecipitation. Shows cross-reactivity to HSV....
Duck polyclonal to Cobra venom - Fab Fragment ( Abpromise for all tested applications). Antigen: Snake Venom of N. naja arta...
LIGHT DIAGNOSTICS Echovirus Blend Reagent, ~50 tests, included in kit #3340 & #3365...
ICAD / DFF45 (NT) Affinity Purified Polyclonal Antibody...
Biology Products: